 |
INTRODUCTION |
It is well established that the risk of developing coronary heart
disease is inversely proportional to plasma
HDL1 cholesterol and apoA-I
levels (1, 2), suggesting that HDL is protective against the
development of atherosclerosis. The premise that HDL and apoA-I are
protective against atherosclerosis is supported by studies showing that
expression of human apoA-I in transgenic mice protects against the
development of aortic lesions (3) and decreases atherosclerosis in
apoE-deficient (4, 5) and apo(a)-transgenic mice (6). The most widely accepted model explaining the anti-atherogenic properties of apoA-I is
reverse cholesterol transport (7). In this process, poorly lipidated
apoA-I first removes excess free cholesterol from peripheral cells
through a mechanism dependent on ABCA1 (8). ApoA-I then acts as a
co-factor for LCAT, which catalyzes formation of cholesteryl ester
(CE), resulting in the conversion of the poorly lipidated apoA-I to a
spherical HDL particle. After being remodeled by cholesteryl ester
transfer protein, hepatic lipase, and phospholipid transfer protein,
HDL delivers its CE either to the liver, where it can be excreted or
repackaged into new lipoproteins, or to ovaries, testes, and adrenal
glands, where it can be used in the production of steroid hormones.
The importance of apoA-I in reverse cholesterol transport has been
confirmed by the creation of mice deficient in this apolipoprotein. Compared with apoA-I+/+ mice,
apoA-I
/
mice have an ~70% reduction in
total plasma cholesterol and HDL cholesterol (9-11). In addition, LCAT
activity in the plasma of the apoA-I
/
mice
is 75% lower than in apoA-I+/+ mice. Reduced
LCAT activity is directly linked to the absence of apoA-I because
addition of apoA-I to apoA-I
/
plasma
restores LCAT activity to near normal levels (12). In addition to the
decrease in plasma HDL levels, apoA-I
/
mice
have a dramatic decrease in CE accumulation in the cortical cells of
the adrenal gland, luteal and interstitial cells of the ovary, and
Leydig cells of the testis (13). This reduction appears to reflect the
absence of apoA-I and not simply the reduced HDL levels because
apoA-II
/
mice have near normal CE levels in
steroidogenic cells despite having plasma HDL and HDL CE levels
equivalent to those in the apoA-I
/
mice
(13). This result suggests a specific effect of apoA-I on CE
accumulation in steroidogenic cells.
HDL provides cholesterol to cells via a selective uptake pathway in
which HDL CE and free cholesterol (FC) are taken into the cell without
the uptake and lysosomal degradation of the HDL particle (14-19). The
selective delivery of HDL cholesterol to cells differs from the
classical LDL receptor pathway in which lipoprotein particles are
degraded in lysosomes to release the constituent lipids for use by the
cell (20). The selective uptake pathway is the major route for the
delivery of HDL CE to the liver and steroidogenic cells of rodents
in vivo and in vitro (14, 17). In steroidogenic
cells this pathway accounts for up to 90% of the cholesterol destined
for steroid production or CE storage.
Recent studies indicate that scavenger receptor BI (SR-BI) is the cell
surface receptor responsible for HDL CE-selective uptake (21-23).
SR-BI is a 57-kDa, 509-amino acid protein that is highly conserved
among human, mouse, rat, hamster, and cow (21, 24-28). Evidence that
SR-BI is a selective uptake receptor was provided by studies showing
that SR-BI is expressed in tissues exhibiting high rates of HDL
CE-selective uptake and is regulated in parallel to steroid production
(21, 29-32). Direct evidence for SR-BI function was provided by
studies in which antibody to the extracellular domain of SR-BI
inhibited delivery of HDL CE to the steroidogenic pathway in murine
adrenocortical cells (33). Inactivation of the SR-BI gene in mice
increased plasma HDL cholesterol levels and reduced neutral lipid
stores in the adrenal gland and ovary (34, 35). Mice carrying an
induced mutation that reduced hepatic SR-BI expression levels by 50%
also showed a reduction in HDL CE-selective uptake (36). These studies
are complemented by studies in which hepatic SR-BI was overexpressed by
either an adenovirus vector (37) or via a transgene (38, 39). In these studies SR-BI overexpression decreased HDL cholesterol and apoA-I levels, increased the plasma clearance of apoA-I, and increased hepatic
HDL CE-selective uptake (38). Taken together, these data indicate that
SR-BI plays a key role in mediating HDL CE-selective uptake by cells of
the liver and steroidogenic organs and in determining the plasma levels
of HDL cholesterol in mice.
The severe depletion of CE in steroidogenic cells of
apoA-I
/
mice suggests that apoA-I plays a
specific role in the HDL CE-selective uptake process mediated by SR-BI
in vivo. The nature of this role, however, is unclear
because a variety of lipoproteins and apolipoproteins can bind to SR-BI
expressed in transfected cells (24, 40, 41). In addition, reconstituted
HDL containing apoA-I, apoE, or apoA-II + apoC proteins are all active
in HDL CE-selective uptake into cultured adrenal cells (42). In the
present study we tested the role of apoA-I in SR-BI-mediated HDL
CE-selective uptake by analyses of the biochemical properties of
apoA-I
/
HDL and the functional interaction
of these particles with SR-BI on adrenocortical cells, hepatoma cells,
and cells expressing a transfected SR-BI. The results show that large
CE-rich apoA-I
/
HDL bind to SR-BI with the
same affinity as apoA-I+/+ HDL. In contrast,
apoA-I
/
HDL show a reduced
Vmax for CE transfer from the HDL particle to
the cell. These results indicate that the absence of apoA-I results in
HDL particles with a reduced capacity for SR-BI-mediated CE-selective
uptake. The reduced Vmax for HDL CE transfer
likely contributes to the severe reduction in CE accumulation in
steroidogenic cells of apoA-I
/
mice.
 |
EXPERIMENTAL PROCEDURES |
Materials--
The following reagents used for culturing the
ldlA[mSR-BI], Fu5AH, and Y1-BS1 cells were purchased from the listed
venders: poly-D-lysine (BD PharMingen), EMEM
(Bio-Whittaker), heat-denatured fetal bovine serum (Atlanta
Biologicals), 100× penicillin/streptomycin/glutamine, DMEM/F-12 medium
(Invitrogen), 6- and 12-well plates (Costar), Cortrosyn (Organon), and
Ham's F-10 medium, Ham's F-10-HEPES medium, and heat-denatured horse
serum (Sigma). Sodium [125I]iodide and
[3H]cholesteryl oleoyl ether were acquired from
PerkinElmer Life Sciences and Amersham Biosciences, respectively.
Animals--
C57BL/6J-Apoa1tm1Unc (10) and "wild
type" apoA-I+/+ C57BL/6J were purchased from
the Jackson Laboratory, and colonies were established at the Scripps
Research Institute and, subsequently, at the La Jolla Institute for
Molecular Medicine. At the State University of New York (Stony Brook,
NY), the C57BL/6J-Apoa1tm1Unc mice were cross-bred with
apoA-I+/+ FVB/N mice to overcome the
reproductive deficiency of the C57BL/6J-Apoa1tm1Unc mice
(small litter size and low survival rate). This was necessary to obtain
sufficient HDL for these studies. Progeny heterozygous for the mutated
apoA-I allele were then mated with apoA-I+/+
FVB/N mice for 3 generations. The genotypes of all offspring were
determined by PCR analysis of genomic DNA as described (10). Heterozygotes having a 8:1 FVB/N:C57BL/6 background were then mated to
generate mice carrying either two normal
(apoA-I+/+) or two mutated copies of the apoA-I
allele (apoA-I
/
).
apoA-I+/+ and apoA-I
/
animals were mated within their respective genotype to achieve the
numbers of animals necessary for the experiments listed below. Additional FVB/N apoA-I+/+ mice were obtained
from Taconic and maintained as a separate colony. All mice were kept on
a 12-h light/12-h dark cycle with standard rodent chow and water
ad libitum. Housing and experimental procedures
were approved by the State University of New York at Stony Brook
Committee on Laboratory Animal Resources and the Scripps Research
Institute Institutional Animal Care and Use Committee.
Isolation of apoA-I+/+ and apoA-I
/
Lipoproteins--
After an overnight fast, mice were anesthetized and
exsanguinated by heart puncture. Cells were removed by centrifugation at 2,000 × g for 30 min at 4 °C. If not used
immediately, plasma was frozen at
80 °C after adding sucrose to a
final concentration of 10%. Prior to isolation of lipoproteins, 0.05%
NaN3, 5 µg/ml aprotinin, 5 µg/ml leupeptin, 1 µg/ml
pepstatin, and 1 mM EDTA (final concentrations) were added.
Lipoproteins in the 1.02-1.21 g/ml density range were isolated by
sequential ultracentrifugation using KBr at 1.02 and 1.21 g/ml,
respectively. Following dialysis against PBS-E (150 mM
NaCl, 10 mM
KxHxPO4, 1 mM EDTA, pH 7.4), an equal amount of
apoA-I+/+ or apoA-I
/
lipoprotein total cholesterol was fractionated by HPLC using a Superose
6 HR 10/30 size exclusion column (Amersham Biosciences) run at a flow
rate of 0.4 ml/min. Using the Cholesterol CII enzymatic assay (Wako),
the total cholesterol concentration was determined for 40 0.4-ml
fractions collected from 10 to 50 min after sample injection.
Analysis of HDL Apolipoproteins and Lipids--
Equal volumes of
fractions 20-30 from the Superose column were diluted with 5× SDS
sample buffer (250 mM Tris-HCl, pH 6.8, 25% glycerol, 10%
SDS, 5%
-mercaptoethanol, 0.25% bromphenol blue), heated for 5 min
at 90-100 °C, and analyzed by 8-20% SDS-polyacrylamide gradient
gel electrophoresis followed by staining with 0.1% Coomassie Brilliant
Blue R-250.
For structural and compositional analysis of the HDL,
apoA-I+/+ fractions 24-30 and
apoA-I
/
fractions 22-30 were pooled,
concentrated using a Centricon 50 (Millipore), and dialyzed against
PBS-E. Total cholesterol, free cholesterol, phospholipid, and
triglyceride concentrations were measured using commercially available
enzymatic kits (Wako). Cholesteryl ester concentration was calculated
by multiplying the difference between total cholesterol and free
cholesterol by 1.68 to account for the mass of the esterified acyl
chain. A modified Lowry assay using horse IgG as a standard (Pierce)
was used for protein measurement (43).
Nondenaturing Gradient Gel Electrophoresis of
apoA-I+/+ and apoA-I
/
HDL--
HDL (25 µg of protein) was analyzed by 4-25% nondenaturing gradient
gel (16 cm × 14 cm × 1.5 mm) electrophoresis at 4 °C. After pre-running the gel at 125 V for 30 min, samples were loaded in
0.045 M Tris borate/0.001 M EDTA, pH 8.3, 10%
sucrose, 0.1% bromphenol blue and run as follows: 25 V for 15 min, 50 V for 15 min, 75 V for 15 min, 125 V for 15 min, and 250 V for 24 h. Proteins were then visualized using 0.1% Coomassie Brilliant Blue R-250.
Density Gradient Ultracentrifugation of HDL--
HDL
radiolabeled with 125I was overlaid on 1 ml of 1.30 g/ml
KBr. A step gradient was created by sequentially adding the following KBr solutions: 3 ml of 1.21 g/ml, 4 ml of 1.12 g/ml, 3 ml of 1.063 g/ml, 1 ml of 1.02 g/ml. The gradient was centrifuged in a SW41 rotor
at 39,000 rpm for 24 h at 15 °C. After collecting 17 0.7-ml fractions from the top to the bottom of the gradient, the samples were
counted for 125I activity and weighed to determine density.
Dynamic Laser Light Scattering Analysis of HDL--
For each HDL
sample, particle diameters were determined optically by dynamic light
scattering analysis with a Microtrac Series 150 Ultrafine particle
analyzer fitted with a flexible conduit-sheathed probe tip (UPA-150,
Microtrac, Clearwater, FL) (44). Particles were assumed to be
transparent and non-spherical with a density of 1.16 g/ml and a
refractive index of 1.46. Raw particle-size distributions were
converted to population percentiles, which were used to calculate
median particle diameter for each decile of lipoprotein size distribution.
Radiolabeling of HDL--
Under a stream of N2, 100 µCi of [3H]cholesteryl oleoyl ether
([3H]COE) was dried onto a 4-ml glass scintillation vial.
To the vial was added 4-5 mg of 1.02-1.21 g/ml lipoprotein and 50 µg of recombinant cholesteryl ester transfer protein (provided by Ron
Clark, Pfizer). After bringing the final volume to 1.5 ml with PBS-E,
the reaction was gently stirred at 37 °C for 3 h. The
radiolabeled lipoprotein was concentrated using a Centricon 50 and
separated on a Superose 6 column. The labeling of the
[3H]COE HDL with [125I]dilactitol tyramine
([125I]DLT) was as described (45). The specific activity
of the [3H]COE-[125I]DLT HDL ranged from 4 to 20 dpm/ng protein for 3H and from 90 to 200 cpm/ng
protein for 125I. apoA-I
/
HDL
used for the competitive binding assay was radiolabeled with Na125I using the iodine monochloride method (46). The
specific activity of the 125I-apoA-I
/
HDL
was 500-2600 cpm/ng of protein.
Cell Culture--
All cell lines were maintained in a 37 °C
humidified 95% air, 5% CO2 incubator. Y1-BS1 cells were
cultured in Ham's F-10 complete medium (12.5% heat-denatured horse
serum, 2.5% heat-denatured fetal bovine serum, 2 mM
glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin). For
experiments, cells were seeded at a density of 0.8 or 1.5 × 106 cells/well into 12- or 6-well plates, respectively,
which had been treated with 100 µg/ml poly-D-lysine.
After 48 h, medium was replaced with Ham's F-10 complete medium
plus 100 nM Cortrosyn, a (1-24)-adrenocorticotropic
hormone (ACTH) synthetic analogue. Experiments were conducted 24 h
later. Fu5AH cells were cultured in EMEM complete medium (5%
heat-denatured fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin). Experiments were
conducted 48 h after plating. ldlA[mSR-BI] cells, which stably
express murine SR-BI (21), were maintained in DMEM/F-12 complete medium
(5% heat-denatured fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin, 250 µg/ml G418).
Experiments were conducted 24 h after plating.
Competitive Binding of apoA-I+/+ and
apoA-I
/
HDL--
Y1-BS1 cells were washed twice with 1 ml of serum-free Ham's F-10-HEPES medium (4 °C). HDL was added such
that the final concentration was 5 µg/ml protein for
125I-apoA-I
/
HDL and 5, 10, 25, or 75 µg/ml protein for unlabeled human HDL3, apoA-I+/+ HDL, and
apoA-I
/
HDL. After 2 h at 4 °C,
cells were washed three times with 0.1% bovine serum albumin/PBS, pH
7.4 and one time with PBS, pH 7.4 (4 °C). Cells were lysed with 0.1 N NaOH, and the lysate was passed three times through a
28-gauge needle. Protein was determined (43), and 125I was
measured in a Packard Cobra-II
counter.
Determination of Cell Association, Degradation, and Selective
Uptake of HDL CE--
Y1-BS1, Fu5AH, and ldlA[mSR-BI] cells in
six-well plates were washed, the medium was replaced with serum-free
Ham's F-10 medium, EMEM, or DMEM/F-12, respectively, and
[3H]COE-[125I]DLT
apoA-I+/+ or
[3H]COE-[125I]DLT
apoA-I
/
HDL was added to the indicated
concentration. Following a 4-h incubation at 37 °C, cells were
washed three times with PBS plus 0.1% bovine serum albumin, pH 7.4, one time with PBS, pH 7.4, lysed with 0.1 N NaOH, and
passed five times through a 28-gauge needle. The lysate was then
processed to determine trichloroacetic acid-soluble and -insoluble
125I radioactivity and organic solvent-extractable
3H-radioactivity as described (45, 47). Trichloroacetic
acid-insoluble 125I radioactivity represents
cell-associated HDL apolipoprotein, which is the sum of cell
surface-bound apolipoprotein and endocytosed apolipoprotein that is not
yet degraded. Trichloroacetic acid-soluble 125I
radioactivity represents endocytosed and degraded apolipoprotein that
is trapped in lysosomes because of the dilactitol tyramine label (45,
48). The sum of the 125I-degraded and
125I-cell-associated undegraded apolipoprotein expressed as
CE equivalents was subtracted from the CE measured as extractable
3H radioactivity to give the selective uptake of HDL CE
(45, 47). Values for these parameters are expressed as nanograms of HDL
CE/mg of cell protein. Binding and kinetic parameters were calculated
by fitting the data to a one-site model using GraphPad Prism 3.00 (GraphPad Software Inc.).
 |
RESULTS |
Compositional Analysis of FVB/N apoA-I+/+ and
apoA-I
/
HDL--
Prior to functional analysis of
apoA-I+/+ and apoA-I
/
HDL, the structural and compositional properties of the particles were
defined because previous studies were unclear as to the effect of
apoA-I deficiency on particle size and the content of CE and TG (9, 11). Fractionation of lipoproteins within the density range of
1.02-1.21 g/ml by gel filtration chromatography showed that apoA-I
/
HDL was larger than
apoA-I+/+ HDL (Fig.
1A) as noted previously (9).
Similar results were seen by nondenaturing gradient gel electrophoresis
(Fig. 1A, inset) and by dynamic laser light
scattering (Fig. 1B). apoA-I+/+ HDL
was mainly composed of particles approximately 11 nm in diameter. In
contrast, apoA-I
/
HDL had a mean size of
13.1 nm with a broader distribution of particles, ranging from 10 to 17 nm in diameter, and with no evident lipoprotein subclasses. Consistent
with these properties, density gradient ultracentrifugation showed
apoA-I
/
HDL to have a broader distribution
with a peak density of 1.075 g/ml compared with 1.10 g/ml for
apoA-I+/+ HDL (data not shown).

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
Analysis of particle size and heterogeneity
of apoA-I+/+ and
apoA-I /
HDL. A, 1 mg of 1.02-1.21 g/ml
apoA-I+/+ and apoA-I /
lipoprotein total cholesterol was separated by HPLC using a Superose 6 column at a flow rate of 0.4 ml/min. Fractions collected from 10 to 50 min after the initial injection of the sample were analyzed for total
cholesterol content. After pooling and concentrating
apoA-I+/+ fractions 24-30 and
apoA-I / fractions 22-30, 25 µg of HDL
protein was analyzed by 4-25% non-denaturing gradient gel
electrophoresis and visualized using 0.1% Coomassie Brilliant
Blue R-250 (inset). B, particle diameters of
apoA-I+/+ and apoA-I /
HDL were determined optically by dynamic laser light scattering as
detailed under "Experimental Procedures." Each point
represents the mean of six measurements (± S.E.) collected for two
separately isolated batches of HDL.
|
|
Compositional analysis of the FVB/N HDL showed that
apoA-I
/
HDL had significantly more FC and
phospholipid (PL) compared with apoA-I+/+ HDL
but very similar percent compositions of the core lipids, primarily CE.
Because a previous analysis with C57BL/6 mice indicated that
apoA-I
/
HDL had a lipid core of mainly TG
(11), HDL from mice with a C57BL/6 genetic background was also examined
(Table I). Like FVB/N
apoA-I
/
HDL, the C57BL/6
apoA-I
/
HDL was enriched in FC and PL
compared with apoA-I+/+ HDL with a core that was
primarily CE and not TG. The reason for the discrepancy in CE and TG
content with the previous report is unclear (11).
The apolipoprotein distribution within HDL was analyzed by separating
fractions 20-30 from the gel filtration profile (Fig. 1) on 8-20%
SDS-polyacrylamide gradient gels. In apoA-I+/+
HDL, apoA-I and apoA-II/apoC proteins were similarly distributed across
the HDL peak (Fig. 2A).
ApoA-IV was localized to the front side of the HDL peak (fractions
24-27), and a trace amount of apoE was present but restricted mainly
to fractions coincident with apoB (fractions 20-23) and not apoA-I
(fractions 24-30). In contrast to apoA-I+/+
HDL, significant levels of apoE were found throughout the
apoA-I
/
HDL profile (fractions 21-30). ApoA-II was
also present throughout the apoA-I
/
HDL profile, but
the quantitative distribution of apoA-II was shifted to smaller HDL, in
contrast to that of apoE, which was primarily on larger HDL. This
result, as well as the lack of discrete size fractions upon
nondenaturing gradient gel electrophoresis (Fig. 1, inset),
may indicate that apoA-II and apoE reside on the same
apoA-I
/
HDL particles, but that has not been
tested directly. ApoA-IV was also found on the
apoA-I
/
HDL. However, unlike the other
apolipoproteins, apoA-IV was found on particles of similar size in both
apoA-I+/+ and apoA-I
/
HDL (fractions 24-28). This may indicate that apoA-IV forms a separate
population of HDL that is not dependent on apoA-I. It is also important
to note that, for apoA-I+/+ fractions 25-30 and
apoA-I
/
fractions 23-27, the high molecular
protein mass in the 200-500-kDa range most likely represents protein
aggregates and not apoB. This is evident from additional analyses in
which the extent of aggregation was proportional to the amount of
sample loaded (data not shown).

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 2.
SDS-PAGE of
apoA-I+/+ and
apoA-I /
lipoprotein fractionated by gel filtration chromatography.
Following fractionation by HPLC using a Superose 6 column, equal
volumes of apoA-I+/+ and
apoA-I / fractions 20-30 were diluted with
5× reducing SDS sample buffer and separated on 8-20%
SDS-polyacrylamide gradient gels. The proteins were visualized using
0.1% Coomassie Brilliant Blue R-250.
|
|
Functional Properties of FVB/N apoA-I+/+ and
apoA-I
/
HDL--
Functional properties of
apoA-I+/+ and apoA-I
/
HDL were tested using the Y1-BS1 mouse adrenocortical cell line (49).
Like adrenocortical cells in vivo, Y1-BS1 cells respond to
ACTH treatment by up-regulating SR-BI expression and
SR-BI-dependent selective HDL CE uptake (31). SR-BI is the
major route for the selective uptake and the provision of HDL CE to the
steroidogenic pathway in Y1-BS1 cells (33). Similarly, most of the cell
surface high affinity HDL binding by Y1-BS1 cells is the result of
SR-BI, although HDL may bind to low affinity sites as well (33). Before
evaluating the HDL CE-selective uptake properties of
apoA-I
/
HDL, a competitive binding assay was
conducted using 125I-apoA-I
/
HDL
with unlabeled human HDL3, apoA-I+/+
HDL, or apoA-I
/
HDL as competitors (Fig.
3A, inset). The
results showed that all three HDL particles competed similarly for the
binding of the radiolabeled apoA-I
/
HDL.
Hence, the majority of the high affinity binding of
apoA-I
/
and apoA-I+/+
is to the same cell surface binding site that was shown previously with
human HDL3 to be SR-BI (33).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 3.
Cell association, degradation, and selective
uptake of HDL CE by Y1-BS1 cells. ACTH-treated Y1-BS1 cells were
exposed to 2.5-50 µg/ml
[3H]COE-[125I]DLT
apoA-I+/+ ( or ) and
apoA-I / ( or ) HDL for 4 h at
37 °C. The amount of HDL cell association shown in A or
HDL degradation (open symbols) and selective CE
uptake (closed symbols) shown in B
were determined as described under "Experimental Procedures." Each
point on the curve represents the mean of 12 samples (± S.E.) from three experiments using separately isolated
batches of HDL. The curves were created by fitting the data
to a one-site model. Note that the scales of the y axis for
the two panels are different. The
inset shows competition between 5 µg of protein/ml of
125I-apoA-I / HDL and 5, 10, 25, or 75 µg of protein/ml of unlabeled human HDL3,
apoA-I+/+ HDL, or
apoA-I / HDL. After a 2-h incubation at
4 °C, the amount of bound
125I-apoA-I / HDL was determined
as described under "Experimental Procedures." Values are the mean
of four samples (± S.E.) from two experiments.
|
|
The ability of Y1-BS1 cells to internalize CE from the
apoA-I+/+ and apoA-I
/
HDL was tested using HDL doubly labeled with
[3H]cholesteryl oleoyl ether ([3H]COE) and
[125I]dilactitol tyramine ([125I]DLT).
Because these radiotracers are nonhydrolyzable and become irreversibly
trapped within cells, they permit the uptake of both the apolipoprotein
and cholesteryl ester moieties of the HDL to be followed quantitatively
(14, 19, 45, 47). The HDL concentration dependence for the cell
association of apoA-I+/+ and
apoA-I
/
HDL CE (Fig. 3A) showed
that the KD (µg of HDL protein/ml; apoA-I+/+: 21 ± 4 versus
apoA-I
/
: 18 ± 3) and the
Bmax (ng of HDL CE/mg of cell protein;
apoA-I+/+: 340 ± 30 versus
apoA-I
/
: 300 ± 22) for the two types
of HDL were nearly identical, as judged by fitting the data to a
one-site binding model. When expressed on a molar basis, the
KD for cell association was lower for
apoA-I
/
HDL
(apoA-I+/+: 125 ± 25 nM
versus apoA-I
/
: 79 ± 13 nM).
The ability of the Y1-BS1 cells to internalize HDL CE by either
degradative or selective uptake was then analyzed (Fig. 3B). Over an HDL concentration range of 2.5-50 µg/ml protein, 1.5-3-fold more CE was internalized by selective uptake from
apoA-I+/+ HDL compared with
apoA-I
/
HDL. Fitting these data to a
one-site model showed that the difference in selective HDL CE uptake
from the two types of HDL was mainly caused by a difference in
Vmax as opposed to the Km
(Table II). The difference in the
Vmax most likely represents the inability of
SR-BI to efficiently remove the CE core from the
apoA-I
/
HDL. The selective uptake
efficiencies, which are the ratios of HDL CE-selective uptake to HDL CE
cell association, were 1.8-2.8-fold higher for
apoA-I+/+ HDL compared with
apoA-I
/
HDL throughout the concentration
range. Therefore, even when similar amounts of HDL CE were bound to
SR-BI, significantly less CE was internalized from the
apoA-I
/
HDL. Interestingly, the quantities
of HDL taken up and degraded via the endocytic pathway were the same
for both apoA-I
/
and
apoA-I+/+ HDL (Fig. 3B, Table II).
Thus, the difference in HDL CE delivery to the cell from
apoA-I
/
HDL is specific to the
SR-BI-mediated selective uptake pathway. It is unclear whether the low
level of HDL degradation (Fig. 3B) is the result of SR-BI or
of other mechanisms.
View this table:
[in this window]
[in a new window]
|
Table II
Kinetic parameters for degradation and selective uptake of HDL-CE
Values ± S.E. were calculated by fitting the data presented in
Figs. 3 and 5 to a one-site model. Vmax values are
given as nanograms of HDL CE/mg cell protein/4 h. Km
values are given as micrograms of HDL protein/ml.
*Km is the nM HDL value of this
parameter for selective CE uptake derived from fitting the raw data to
a one-site model.
|
|
To determine whether the reduction in selective CE uptake from
apoA-I
/
HDL occurred with other cell types,
studies were done with the Fu5AH and ldlA[mSR-BI] cell lines. The
Fu5AH rat hepatoma cell line was chosen for two reasons. First, this
cell line was derived from rat hepatocytes, which in vivo
internalize the majority of plasma HDL CE by selective uptake (14, 17).
Second, the Fu5AH cells have been shown to naturally express a high
level of SR-BI (50). At 25 µg/ml HDL protein, Fu5AH cells showed
similar amounts of HDL cell association (Fig.
4, panel A) and HDL
degradation (panel B) with
apoA-I
/
and apoA-I+/+
HDL, but showed 3-fold more selective CE uptake from
apoA-I+/+ compared with
apoA-I
/
HDL (panel C).
Interestingly, the HDL cell association and degradation values for
Fu5AH cells were reduced approximately 2-fold compared with Y1-BS1
cells, although the HDL CE-selective uptake values were nearly
identical in both cell types.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
Cell association, degradation, and selective
uptake of apoA-I+/+ and
apoA-I /
HDL CE displayed by Fu5AH and Y1-BS1 cells. Fu5AH and ACTH-treated
Y1-BS1 cells were exposed to 25 µg/ml
[3H]COE-[125I]DLT
apoA-I+/+ and apoA-I /
HDL for 4 h at 37 °C. The amount of HDL cell association
(A), HDL degradation (B), and selective CE uptake
(C) were determined as described under "Experimental
Procedures." Values represent the mean of four samples (± S.E.) from
two experiments. Similar results were seen using a separately isolated
batch of particles.
|
|
The functional properties of apoA-I+/+ and
apoA-I
/
HDL were also studied using the
ldlA[mSR-BI] cell line. These cells selectively internalize CE from
HDL by virtue of a transfected SR-BI cDNA (21) with at least 80%
of the HDL selective uptake caused by SR-BI (33). Like the Y1-BS1
cells, the ldlA[mSR-BI] cells displayed more selective HDL CE uptake
from apoA-I+/+ compared with
apoA-I
/
HDL (Fig.
5C), even though both types of
particles were bound (Fig. 5A) and degraded (Fig.
5B) to similar extents. The KD values for
cell association were similar for both HDLs when expressed on a protein
basis (µg/ml HDL protein; apoA-I+/+: 12.1 ± 1.5 versus apoA-I
/
: 10 ± 1.2). When expressed on a molar basis, the KD for
cell association was lower for apoA-I
/
HDL
(apoA-I+/+: 72.3 ± 9.2 nM
versus apoA-I
/
: 43.5 ± 1.4).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 5.
Cell association, degradation, and selective
uptake of HDL CE by ldlA[mSR-BI] cells. ldlA[mSR-BI] cells
were exposed to 2.5-50 µg/ml
[3H]COE-[125I]DLT
apoA-I+/+ ( ) and
apoA-I / ( ) HDL for 4 h at 37 °C.
The amount of HDL cell association (A), HDL degradation
(B), and selective CE uptake (C) were determined
as described under "Experimental Procedures." Each point
on the curve represents the mean of four samples (± S.E.)
from two experiments. The curves were created by fitting the
data to a one-site model. Note that the scales of the y axis
for the three panels are different.
|
|
The selective uptake efficiencies, which are the ratios of HDL
CE-selective uptake to HDL CE cell association, were 1.5-1.7-fold higher for apoA-I+/+ HDL compared with
apoA-I
/
HDL throughout the concentration
range. The kinetic parameters for HDL CE-selective uptake in Table II
indicate that, as for the Y1-BS1 cells, the difference between the
apoA-I
/
and apoA-I+/+
HDL lies in the Vmax. Interestingly, the
Km values for selective uptake were lower for
apoA-I
/
HDL as compared with
apoA-I+/+ HDL when expressed on a protein basis
or on a particle molarity basis (Table II). A reduction in
Km with apoA-I
/
HDL was
also seen with Y1-BS1 cells, although the difference compared with
apoA-I+/+ HDL was greater with the Y1-BS1 cells
compared with the ldlA[SR-BI] cells. These data show that
apoA-I
/
HDL binds as efficiently or with a
higher affinity compared with apoA-I+/+ HDL, but
shows a reduced selective uptake of CE into adrenocortical cells,
hepatoma cells, and a cell line expressing a transfected SR-BI.
 |
DISCUSSION |
The present results demonstrate structural and functional
differences between apoA-I+/+ and
apoA-I
/
mouse HDL.
apoA-I
/
HDL consisted of particles that were
generally larger and more heterogeneous than
apoA-I+/+ HDL. Although
apoA-I
/
HDL are CE-rich and bind to SR-BI
with a similar affinity compared with apoA-I+/+
HDL, apoA-I
/
HDL show a 2-3-fold decrease
in the Vmax for CE transfer to Y1-BS1 adrenocortical cells. A similar reduction in the efficiency of HDL
CE-selective uptake was seen with Fu5AH hepatoma cells and a lesser
reduction in an SR-BI-expressing CHO cell line. It is unclear why the
quantitative difference in the selective uptake of
apoA-I
/
and apoA-I+/+
HDL CE is less in the transfected CHO cell, but this may be because of
cell type-specific factors that occur in cells naturally expressing SR-BI. These results indicate that the absence of apoA-I results in HDL
particles with a reduced capacity for SR-BI-mediated CE-selective uptake.
The apoA-I
/
mouse has a dramatic reduction
in CE accumulation in steroidogenic cells; adrenocortical cells contain
only 5% of the CE found in apoA-I+/+ adrenal
cells (13). The reduced Vmax of the
apoA-I
/
HDL for HDL CE transfer likely
contributes to, but cannot completely explain, this severe reduction in
adrenal CE accumulation. Additionally, electron microscopic studies
suggest that apoA-I
/
HDL are not well
retained in the microvillar channels that are believed to be the cell
surface compartment in which SR-BI-mediated HDL CE-selective uptake
occurs (13, 51, 52). The failure to retain HDL in microvillar channels
may also contribute to adrenal CE depletion in the
apoA-I
/
mouse. Whether this failure is a
result of the absence of a specific interaction between apoA-I and
microvillar channel components or is the result of other properties
(e.g. size, lipid composition, apolipoprotein content) of
apoA-I
/
HDL is unknown.
The observation that apoA-I
/
HDL binds to
SR-BI with a similar KD (as measured by HDL protein
concentration) or a lower KD (on a molar basis)
compared with apoA-I+/+ HDL is consistent with
previous observations that SR-BI can bind a variety of HDL
apolipoproteins with high affinity (41) and appears to do so by
recognition of the multiple amphipathic
-helical repeat units
present in the apolipoproteins (53). The reduced efficiency of CE
uptake from apoA-I
/
HDL, however, clearly
shows that lipoprotein binding to SR-BI does not translate to
equivalent CE-selective uptake. Lipoprotein properties other than those
needed for docking to SR-BI are important for SR-BI-mediated CE
transfer to the cell. This conclusion is also consistent with the
observation that SR-BI-mediated CE uptake from LDL is 6-7-fold less
efficient than from HDL despite the fact that SR-BI binds LDL with the
same or a higher affinity (24, 54).
An interesting observation from these studies is that the
Km for selective uptake was considerably lower
(2-5-fold) than the KD for HDL cell association.
This was seen with both apoA-I+/+ and
apoA-I
/
HDL in both Y1-BS1 and ldlA[SR-BI]
cells. This was noted previously for human HDL3 interaction
with Y1-BS1 cells (55). The reason for the lower Km
is not known. One speculation is that subsets of SR-BI exist in active
(perhaps occurring as a multimeric complex) and inactive (monomeric?)
forms for HDL CE uptake. If the active form had a higher affinity for
HDL, the KD for binding and the
Km for CE uptake may be more similar in the subset
of active receptors engaged in CE uptake.
Because apoA-I+/+ and
apoA-I
/
HDL differ significantly in their
structural and compositional properties, many factors may contribute to
the reduced selective uptake efficiency of the
apoA-I
/
HDL. Included among these are
potential effects of HDL lipid composition, particle size, and the
increased apoA-II and apoE content, e.g. based on the
chemical compositions and mean value for HDL size and density, the
molecular compositions on a per particle basis indicate that the FC to
PL ratio is greater for the apoA-I
/
HDL
(0.264 ± 0.024) compared with apoA-I+/+
HDL (0.183 ± 0.021). This difference (p = 0.02)
may reduce the fluidity of the PL monolayer and disrupt SR-BI-mediated
transfer of CE from the particle core despite the fact that the
apoA-I
/
HDL contains 1.6-fold more CE.
However, this calculation is based on mean compositional values and may
not account for the heterogeneity of properties that may occur in the
broad size range of apoA-I
/
HDL.
The impact of HDL size on selective CE uptake was first studied by
Pittman et al. (42), who showed that Y1-BS1 cells display more HDL CE-selective uptake from denser compared with more buoyant rat
HDL or reconstituted apoA-I-containing HDL. In contrast, a recent
report showed that SR-BI-expressing CHO cells display higher binding
affinity (56, 57) and selective CE uptake from human HDL with low
compared with high density (57). The results of the latter study
suggested that the major difference in CE uptake was caused by the
altered binding affinity of the more buoyant HDL rather than a
difference in the efficiency of CE transfer from the HDL. Our results
with apoA-I
/
HDL coincide with the former
findings because we observed less selective CE uptake from the larger,
more buoyant apoA-I
/
HDL.
Another factor that could influence selective CE uptake from the
apoA-I
/
HDL is the apolipoprotein complement
of the particles. Compared with apoA-I+/+ HDL,
apoA-I
/
HDL lack apoA-I and are enriched in
apoE and apoA-II. An inhibitory effect of apoE was suggested by the
observation that the in vivo clearance of CE from apoE-rich
HDL1 in the rat is slower compared with the clearance of CE
from apoE-free HDL (58). In contrast, Arai et al. (59)
observed that selective uptake of HDL CE is enhanced by the cellular
expression of apoE although it was not determined whether this effect
was caused by apoE altering HDL binding or CE transfer from the HDL.
With regard to apoA-I, Pittman et al. (42) showed that
Y1-BS1 cells displayed the highest level of selective CE uptake from
reconstituted HDL containing apoA-I as compared with apoA-II/Cs or
apoE. Similarly, Pilon et al. (60) reported that
displacement of apoA-I on human HDL by apoA-II increased HDL binding
but decreased selective HDL CE uptake by a human adrenocortical cell
line. Studies with human hepatocytes and hepatoma cells also showed
greater CE-selective uptake from HDL containing only apoA-I compared
with HDL containing both apoA-I and apoA-II (61). These results suggest
that apoA-I may enhance whereas apoA-II may inhibit SR-BI-mediated HDL
CE-selective uptake. Both of these possibilities could contribute to
the reduced efficiency of HDL CE-selective uptake with
apoA-I
/
HDL. However, de Beer et
al. (62) observed that CHO cells expressing SR-BI displayed less
binding and more selective CE uptake from recombinant discoidal HDL
prepared with apoA-I and apoA-II compared apoA-I alone. All of these
studies, including the present results, are consistent with the idea
that specific HDL apolipoproteins may influence the actual CE transfer
process mediated by SR-BI, although the multiple variables and
different experimental models in these studies preclude a clear
interpretation at this time.
The increased size and heterogeneity of the
apoA-I
/
HDL suggest that apoA-I plays a key
role in limiting the enlargement of HDL particles during circulation in
the blood. The formation and enlargement of spherical HDL depend on CE
synthesis by LCAT (7). Although plasma LCAT activity is substantially
reduced in the apoA-I
/
mouse (12), there is
clearly sufficient activity to generate large CE-rich HDL. Two
scenarios may be suggested for the generation of the large, CE rich
apoA-I
/
HDL in vivo. The first is
an increased circulation time of the apoA-I
/
HDL, which would permit LCAT to slowly enlarge the HDL CE core. The
data of Plump et al. (11) would argue against this idea because they observed no difference in the fractional catabolic rates
of apoA-I+/+ and
apoA-I
/
HDL CE.
The second scenario is that, in the absence of apoA-I, HDL particles
fuse to form larger HDL. There is some precedent for this possibility
in that apoA-I will prevent the in vitro fusion of LDL with
cholesteryl ester microemulsion particles (63). Perhaps the absence of
apoA-I leads to HDL particle fusion in the
apoA-I
/
mouse, a process that would be
expected to generate large particles with excess surface components.
Consistent with this possibility is that the surface (% protein + FC + PL) to core (% CE + TG) ratio for the
apoA-I
/
HDL (2.2) is nearly the same as this
ratio for apoA-I+/+ HDL (2.1) despite the fact
that the apoA-I
/
HDL are larger and would be
expected to have a reduced surface to core ratio. Based on the average
particle diameters of 11 and 13.1 nm for
apoA-I+/+ and apoA-I
/
HDL (Fig. 2A), respectively, and a surface monolayer
thickness of 2.15 nm (64), the predicted surface to core ratio for
apoA-I
/
HDL can be calculated to be 70% of
the value for apoA-I+/+ HDL. The observation
that the surface to core ratios for the two particles are nearly
identical suggests that the apoA-I
/
HDL has
an excess of surface components, a result consistent with the formation
of large apoA-I
/
HDL via fusion of smaller
particles. Irrespective of whether apoA-I limits HDL size by preventing
particle fusion or by defining maximum particle size, or both, this
appears to be a unique property of apoA-I that is not shared by apoA-II
or the other apolipoproteins that accumulate on the large
apoA-I
/
HDL.
In summary, these results demonstrate major structural differences
between apoA-I+/+ and
apoA-I
/
HDL that translate to differences in
SR-BI-mediated HDL CE-selective uptake but have little effect on HDL CE
uptake by the endocytic pathway. The absence of apoA-I leads to the
formation of HDL particles that bind to SR-BI with the same or greater
affinity compared with apoA-I+/+ HDL but have a
reduced Vmax for SR-BI-mediated CE uptake. This reduced Vmax illustrates that HDL properties
necessary for binding to SR-BI are distinct from those properties
necessary for the transfer of HDL CE to the cell. The reduced
Vmax of apoA-I
/
HDL
likely contributes to the severe reduction of CE accumulation seen in
adrenal cells of the apoA-I
/
mouse.